^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3R1 M326I

    i
    Other names: PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1, Phosphatidylinositol 3-Kinase 85 KDa Regulatory Subunit Alpha, Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha), Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha, Phosphoinositide-3-Kinase Regulatory Subunit Alpha, PtdIns-3-Kinase Regulatory Subunit Alpha, PI3K Regulatory Subunit Alpha, PI3-Kinase Subunit P85-Alpha, GRB1, Phosphatidylinositol 3-Kinase, Regulatory Subunit, Polypeptide 1 (P85 Alpha), Phosphatidylinositol 3-Kinase
    Entrez ID:
    5295
    Related biomarkers:
    Expression
    Mutation
    Others
    over2years
    Conjunctival Melanoma in Ireland – a sixty year review (ECP 2022)
    Conjunctival melanoma is a rare neoplasm with only 72 cases diagnosed in Ireland in the last 60 years. Recurrence and metastases are common. Options for treatment of conjunctival melanoma include excision, cryotherapy, corneal epitheliectomy, radiotherapy and topical mito-mycin C. Adjuvant therapy is limited, with conjunctival melanomas showing intermediate sensitivity to immunotherapy.
    Review • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1)
    |
    PIK3CA mutation • PIK3R1 mutation • PIK3R1 M326I